To address the concern around the efficiency/cytotoxicity ratio and the tumor-targeting effects of polyethylenimine (PEI), is a non-viral gene vector used for the delivery of the cancer therapy gene, poloxamer 407 (P407)-PEI-K12, was synthesized by cross-linking low-molecular weight PEI with P407 and further coupling a bifunctional peptide, K12, which is comprised of the tumor-targeting peptide tLyP-1 and the nuclear localization sequence. Furthermore, the addition of free P407 into the polymer/DNA complex solution produced a temperature-sensitive in situ gel-P407/P407-PEI-K12/DNA complex, which improved the effects of sustained-release gene delivery and transfection efficiency. The specificity, cytotoxicity and gene transfection efficiency of P407-PEI-K12 was investigated in Hela cells in vitro. The polymer efficiently prevented the degradation of plasmid DNA by DNase I and had a marked ability for serum tolerance. Agarose gel electrophoresis revealed that plasmid DNA was efficiently condensed and protected. The higher transfection efficiency of P407-PEI-K12h (the molar ratio of P407-PEI and K12 is 1:10) was achieved with a polymer and plasmid DNA ratio (w/w) of 20:1. The ability of free P407 to promote the transfection of the polymer/DNA complex was high (0.09%). The half-life of the P407/P407-PEI-K12-h/DNA gel complex was 228 min, and the transfection efficiency of the P407/P407-PEI-K12-h/DNA complex was markedly higher compared to that of the P407-PEI-K12-h/DNA complex at various release times.
Introduction
Cancer is one of the most serious health-threatening diseases, which is caused by unregulated gene damage and mutations. Research in this area is therefore crucial; gene-targeting cell therapy is already presenting great potential in the treatment of cancer (1) . Vectors, including viral and non-viral types, can be used to deliver therapeutic DNA into target cells. Non-viral vectors have recently attracted marked interest because of their unlimited carrying capacity, controllable chemical structure, low toxicity and low levels of induced immune responses (2) . Due to its strong cell adhesion and good transfection capacity, polyethylenimine (PEI) is a favorable transgenic non-viral vector (3, 4) ; however, the major drawbacks of PEI are a negative ratio between transfection efficiency and cytotoxicity, and a lack of tumor targeting (5) . To overcome these problems, PEI is linked by degradable linkers, including ester, β-aminoester and disulphide, to obtain short PEI chains that present higher efficiency and lower cytotoxicity (6) . In the present study, low molecular weight (LMW) PEI was cross-linked with P407, in order to synthesize the PEI-derivate P407-PEI, which may have a high transfection efficiency and may degrade into low cytotoxic LMW PEI. TLyp-1 peptide is a tumor-homing and penetrating peptide that contains the (R/K)XX(R/K) motif. It has been reported that tLyp-1 improves the penetration of nanoparticles across the cell membrane (7) . In addition, the nuclear localization sequence (NLS) is an array of proteins that promotes DNA delivery into the nucleus (8) . In the present study, a novel chimeric peptide tLyP-1-NLS (Pro-Lys-Lys-Ly s-Arg-Lys-Val-Cys-Gly-Asp-Lys-Arg-Trp-Arg), named K12, was synthesized by combining the tumor-targeting peptide tLyP-1 and the NLS; K12 is expected to exhibit highly selective expression and promote the delivery of DNA complexes into the nucleus. In the present study, P407-PEI-K12 was synthesized by cross-linking the peptide K12 with P407-PEI; P407-PEI-K12 may improve tumor targeting and increase Addition of free poloxamer 407 to a new gene vector P407-PEI-K12 solution forms a sustained-release in situ hypergel that enhances cell transfection and extends gene expression cellular uptake of genes. It has previously been demonstrated that a similar vector, P123-PEI-R11, has a high transfection efficiency with moderate cytotoxicity (9) . In the present study, free P407 was added to the P407-PEI-K12 solution to form a temperature-sensitive type of in-situ gel-P407/P407-PEI-K12/DNA complex, in order to achieve sustained release of P407-PEI-K12/DNA complex and increase transfection efficiency.
Temperature-sensitive polymers have been widely used to develop temperature-sensitive vehicles for drug delivery. Poloxamers are triblock copolymers comprised of two hydrophilic end blocks of polyethylene oxide (PEO) and a central hydrophobic block of polypropylene oxide (PPO). The length of the polymer block highly affects the nonionic and structural arrangement of PEO-PPO-PEO, which has an amphiphilic and thermoresponsive character (10) . P407, a nonionic thermosensitive, poly(ethylene oxide)-block-poly(propylene oxide)-block-poly (ethylene oxide) copolymer, exists in liquid and gel states at 4-5˚C and high temperatures, respectively, and turns from a low viscosity solution into a gel at a concentration of 18% (w/v) (11) (12) (13) . Due to its thermogelation properties, low toxicity and good biocompatibility; P407 may therefore represent a novel drug-controlled release carrier (14) . Previous studies have also demonstrated the extended and localized viral gene expression of P407 in vivo (15, 16) . The P407/CA/GA gel remains in a gel state in the medium for >1 month (17) . Analysis of P407 and poloxamer 188-based thermoresponsive ketorolac tromethamine in situ gel preparations has confirmed that such gels are able to prolong and control drug release (18) .
Not only does P407 possess thermogelation properties, but it also enhances cell transfection. Previous studies have reported that free poloxamers accelerate recombinant adeno-associated virus-mediated transgene expression in various types of tissue and improve transfection efficiency by minimizing cell injury (19, 20) . Novel strategies that increase the gene contact time via formation of in situ gels may allow more stable gene expression. In the present study, P407-PEI-K12 reduced PEI-induced cytotoxicity, improved tumor targeting and upregulated gene cellular uptake. Furthermore, free P407, a temperature-sensitive type in situ gel with active tumor targeting and therapeutic efficiency enhancement, was added into P407-PEI-K12 solution, in order to form a novel hydrogel complex leading to stable released gene expression, enhanced cell transfection and prolonged gene expression.
Materials and methods
Materials. PEI (2 kDa, PEI 25 kDa), N-succinimidyl-4 -(N-maleimido-methyl) cyclohexane-1-carboxylate (SMCC), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), Ethidium bromide and DNase I were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Sephadex G-25 and Dulbecco's modified Eagle's medium (DMEM) was provided by Pharmacia (Milton Keynes, UK). Dimethyl sulfoxide (DMSO) and triphosgene were purchased from Shanghai Ouyi Biomedicals Branch Company (Shanghai, China). Ultrafiltration centrifuge tubes were obtained from Shanghai Health and Biological Company (Shanghai, China). P407 (MW 12,600 Da) was purchased by BASF Corporation (Mount Olive, NJ, USA), K12 (MW 1,699.11 Da) was synthesized by GL Biochem Ltd. (Shanghai, China). N-hydroxysuccinimide was provided by Shanghai Source Leaf Biotechnology Development Company (Shanghai, China). Toluene, benzene, triethylamine and anhydrous ethanol were provided from Shanghai Ocean University Public Laboratory (Shanghai, China). Hela cells were provided by Shanghai Cell Bank (Shanghai, China). Fetal bovine serum (FBS) and pancreatic enzyme were obtained from Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The bicinchoninic acid (BCA) protein quantitative kit was purchased from Thermo Fisher Scientific, Inc. The purity of the purified and concentrated DNA was determined by measuring ultraviolet absorbance at 260 and 280 nm, respectively. Cell culture lysis reagent (CCLR) was obtained from Promega Corporation (Madison, WI, USA). A luciferase assay system used for the in vitro transfection assay and a pGL3-Control vector with SV-40 promoter and enhancer driving firefly (Photinus pyralis) luciferase were obtained from Promega Corporation. The plasmid-encoding enhanced green fluorescent protein (pEGFP-N2) was kindly provided by the Institute of Life Science and Technology at Tongji University (Shanghai, China). Plasmid pEGFP-N2 and pGL3-Control were obtained from Promega Corporation. The plasmids were amplified using Escherichia coli DH5α and prepared using the Qiangen End-free Plasmid Mega kit provided by the Qiagen GmbH (Hilden, Germany).
Synthesis of P407-PEI.
To produce P407-PEI, P470 was initially activated. To do so, P407 (0.01 mmol) was dried twice in a vacuum by co-evaporation in the presence of anhydrous toluene at 40˚C. It was then dissolved in toluene/dichloromethane (3:1, 40 ml) and treated with bis-(trichloromethyl)-carbonate (0.356 g, 1.2 mmol) overnight. After solution evaporation, the residue was suspended in toluene/dichloromethane (2:1, 30 ml) and treated with solid N-hydroxysuccinimide (0.240 g, 2.0 mmol), followed by anhydrous triethylamine (0.28 ml, 2.0 mmol). After 4 h stirring, the solution was filtered and evaporated. The residue was collected, which represented activated P407. Activated P407 (0.010 mmol) was added to 10 ml anhydrous ethanol to obtain solution A, and 5, 10 and 20-fold molar dehydrated PEI 2 kDa (0.010 mmol) was added to 20 ml anhydrous dichloromethane to obtain solution B. Subsequently, solutions A and B were added to 10 ml anhydrous dichloromethane and the mixture was stirred overnight at room temperature. P407-PEI-5, P407-PEI-10 and P407-PEI-20 were eventually obtained with a molar ratio of PEI/P407 of 5:1, 10:1 and 20:1, respectively. The polymer was dialyzed for 2 days at 4˚C, lyophilized and stored at -20˚C.
Mass spectrometry and High-performance liquid of K12.
Parameters for MS analysis were ESI ion source, probe bias of +4.5KV, the rate of Nebulizer Gas Flow is 1.5L/min, CDL of -20.0V, the temperature of CDL is 250˚C, the rate of T.Flow is 0.2 ml/min, the Block temperature is 200 urce, probe bias of +4.5KV, the ratKromasil C18 column (4.6x250 mm, 5 µm) was selected as a chromatographic column. Gradient elution was performed using acetonitrile (A) and H 2 O (B) with the following linear gradient combinations: 10% A-90% B (0-0.01 min), 35% A-65% B (0.01-25 min), 100% A-0% B (25-25.1 min). The column temperature was 25˚C. The flow rate was 1.0 ml/min, and 20 µl samples were injected. The detection wavelength was 220 nm.
Conjugation of P407-PEI with K12
. Polymer P407-PEI was conjugated with the K12 peptides using SMCC as a crosslinker (21) . SMCC solution (3.33 mg/ml) was added to the P407-PEI solution (10 mg/ml) at the optimal molar ratio of 10:1 and gently stirred for 30 min at room temperature. The non-conjugated SMCC was removed by gel chromatography (Sephadex G-25; Pharmacia, Milton Keynes, UK). Thus, N-hydroxysuccinimide (NHS) eaters of SMCC have reacted with primary amines of P407-PEI to form amide bonds and produce the maleimide-activated P407-PEI. Subsequently, 10 mg/ml K12 was mixed with the maleimide-activated P407-PEI at a molar ratio of 2:1 and 10:1, respectively, and then stirred in the dark overnight at 4˚C prior to lyophilization. Two polymers were obtained and 2:1 was used to obtain P407-PEI-K12-l and 10:1 was used to obtain P407-PEI-K12-h. P407-PEI-K12-l and P407-PEI-K12-h were eventually dissolved in deuterium oxide, and a 1 H-nuclear magnetic resonance (NMR) spectral analysis was carried out at room temperature. First, 10 mg of P407-PEI and P407-PEI-K12 was dissolved in 0.6 ml of deuterium oxide (D 2 O) in a nuclear magnetic resonance (NMR) tube, and the 1 H NMR spectrum was recorded using a 300-mHz spectrometer at room temperature. The MW and distribution of the polymer was determined by gel permeation chromatography with multiangle laser light scattering and a laser wavelength of 690 nm, using a TSK-GEL G5000PWXL column (temperature 40˚C) operated at a flow rate of 0.4 ml per min. Ammonium acetate 0.2 M was used as the mobile phase.
Buffering capacity of P407-PEI-K12. The newly synthesized polymer P407-PEI-K12 was prepared in 50 ml flasks (0.2 mg/ml, 30 ml), and the pH was adjusted to 10.0 with 0.1 M HCl.
Particle size, zeta potential measurement and morphologic observation. Charge ratio (w/w) of the P407-PEI-K12/DNA complex was expressed as the ratio of P407-PEI-K12 and DNA weights. The complex was formed by self-assembly after mixing the Plasmid DNA and polymer solutions (0.1 M PBS, pH 7.4) at a desired charge ratio. The complex prepared was then incubated for 30 min at 37˚C. Particle size and zeta potential of the polymer/DNA complex were then measured in PBS and at room temperature using an electrophoretic light-scattering spectrophotometer with a 90˚ scattering angle.
Once the complexes P407-PEI-K12 and P407-PEI-K12/DNA were synthesized, a drop of the complex solution was placed on a copper grid. The sample was natural air-dried and the splutter coating was spray-gold and the morphological characteristics of P407-PEI-K12 and P407-PEI-K12/DNA were observed by scanning electron microscopy.
Agarose gel retardation assay. In order to examine the ability of the polymers to condense plasmid DNA, various w/w ratios of polymer/DNA complexes were prepared. Briefly, 10X loading buffer (1 µl) was added to 5 µl P407-PEI-K12/DNA complex solution. A total of 10 µl sample was then loaded onto 1% (w/v) the gel and electrophoresis was run for 40 min at 120V. The gel was eventually stained with ethidium bromide for ~20 min at room temperature and illuminated on an ultraviolet illuminator to locate DNA.
Resistance to DNase I digestion and serum. DNase I solution was added to 50 µl complex solution in 1.5 ml tubes and incubated at 37˚C for 30 min. The range of DNase I doses per Plasmid DNA (pDNA) weight unit was between 3 and 72 U DNase I/µg DNA. Subsequently, 2 µl 250 mM EDTA solution was added to each tube and incubated at room temperature for 10 min to inactivate DNase I. Then, 6 µl 10 mg/ml sodium heparin was added to each tube and incubated at room temperature for 2 h to completely dissociate the complex. Agarose gel electrophoresis was performed as previously described to analyze the stability of the complex to DNase I digestion. In addition, various concentrations of FBS (10 µl containing 10, 25 and 50% serum) were added to the complex solution and incubated at 37˚C for 60 min. The sensitivity of P407-PEI-K12 to serum was also determined by agarose gel electrophoresis.
Cytotoxicity assay. The cytotoxicity of P407-PEI-K12 was measured by MTT assay. Hela cells were seeded at a density of 5,000 cells per well in 200 µl growth medium (DMEM) supplemented with 10% FBS in a 96-well plate and incubated for 48 h at 37˚C in a humidified incubator containing 5% CO 2 . The culture medium was replaced with 200 µl serum-free media with increasing concentrations of P407-PEI-K12 (4, 8, 16, 24 and 32 µl/ml). After 24 h incubation at 37˚C in a humidified incubator containing 5% CO 2 , medium was replaced with 20 µl 5 mg/ml sterilized MTT solution and 180 µl fresh growth medium and maintained at 37˚C for 4 h. Subsequently, the MTT/growth medium was replaced with 150 µl DMSO and incubated for 10 min at room temperature. The absorbance value at 570 nm was measured using an ELISA plate reader with background subtraction. Cell viability was calculated with the following equation: Cell viability (%)=(Absorbance of cells treated with nanoparticles-Absorbance of free medium alone)/(Absorbance of control untreated cells-Absorbance of free medium alone) x 100.
Gel preparation and determination of release rate
Preparation of P407 gel and determination of the release rate of P407 gel. P407 solutions (20-23%) were prepared in 0.1 M PBS at 4˚C. Firstly, the glass vial weight was recorded. P407 solution (20%, 2 g) was added to the vial and heated at 37˚C in a water bath, to allow the formation of a hydrogel. The weights of the vial and the gel were recorded. Subsequently, 1 ml PBS was added to the vial containing the P407 hydrogel. After 40 min, the PBS containing the released P407 was pipetted out from the vial, and the weight of the vial with the unreleased gel was recorded. Then, 1 ml PBS was added again, and aliquots of the same PBS were pipetted out at regular intervals for ~40 min, before assessing the weight of the bottle with the unreleased gel. The amount of gel released was determined at the same intervals and the gel release rate was calculated. The same method was used to determine the release rate of 21, 22 and 23% P407 gels.
Synthesis of P407/P407-PEI-K12-h/DNA complex gel.
The freshly prepared P407-PEI-K12-h/DNA complex was mixed at 4˚C, with free P407 (mass ratio 8.75:1 and 21%) to form a P407/P407-PEI-K12-h/DNA complex solution.
Determination of the release rate of P407/P407-PEI-K12-h/DNA complex gel. Firstly, the glass vial weight was recorded. Approximately 2 g P407/P407-PEI-K12-h/DNA solution was added to the vial kept and heated at 37˚C in a water bath, to allow the formation of the hydrogel; the vial weight was then recorded. Subsequently, 1 ml serum-free medium was added to the hydrogel and heated in a water bath at 37˚C. After 40 min, the release medium containing the released polymer/DNA complex was removed from the vial, and the weight of the vial containing the unreleased gel was recorded. Then, 1 ml serum-free medium was added repeatedly in the vial and removed at regular intervals for ~40 min prior to calculating the gel release rate.
In vitro gene transfection In vitro gene transfection of P407-PEI-K12/DNA complex.
The transfection efficiency qualitative and quantitative of P407-PEI-K12 was measured using the plasmid pEGFP-N2 and pGL3-Control, respectively, in Hela cells. A total of 1x10 5 Hela cells were cultured in a 24-well plate for 18-24 h with 500 µl DMEM containing 10% FBS, in order to reach 80% confluence. Culture medium was then replaced with 400 µl serum-free medium and 100 µl freshly prepared P407-PEI-K12/DNA solution containing 2.5 µg plasmid pEGFP-N2 or pGL3-Control at various weight ratios (5, 10, 20, 30) . The cells were incubated at 37˚C with 5% CO 2 for 4 h. After 4 h, culture medium was replaced with 500 µl medium containing 10% FBS and incubated at 37˚C with 5% CO 2 for 48 h. The pEGFP-N2 expression was observed under an inverted fluorescence microscope.
In order to evaluate the transfection effect quantitatively using plasmid pGL3-Control, the luciferase assay was carried out according to the manufacturer's protocol. Culture medium was replaced with 100 µl cell culture lysis reagent (CCLR) and stirred for 30 min at room temperature. Luciferase activity was measured with a luminometer (Turner Designs Luminometer Model TD-20/20; Promega Corporation, Madison, WI, USA). BCA protein assay kit was used to measure protein contents and transfection efficiency for the pGL3-Control. Results were expressed as relative light units (RLUs) against the corresponding protein contents.
In vitro gene transfection of P407-PEI-K12/DNA complex with various concentrations of free P407. After harvesting with 0.25% trypsin, the cells at a density of 1x10 5 cells per well were seeded into 24-well plates at 37˚C with 5% CO 2 . Culture medium was replaced with 400 µl serum-free medium containing free P407 and 100 µl freshly prepared solution of the polymer/DNA at various concentrations (0, 0.06, 0.09 or 0.12%) and containing 2.5 µg plasmid pGL3-Control. The cells were incubated at 37˚C with 5% CO 2 for 4 h. After 4 h, culture medium was replaced with 500 µl medium containing 10% FBS and incubated at 37˚C with 5% CO 2 for 48 h. Culture medium was then replaced with 100 µl CCLR and stirred for 30 min at room temperature. The data assessment was performed as previously described.
In vitro gene transfection of P407/P407-PEI-K12-h/DNA complex gels at various release times.
After cell harvesting with 0.25% trypsin, cells at a density of 1x10 5 cells per well were seeded into 24-well plates at 37˚C with 5% CO 2 . Preliminary experiments demonstrated that complex gels were entirely released after 5 h at 37˚C. The release solutions were then collected at 5, 10, 30, 60, 120 and 300 min. The P407/P407-PEI-K12-h/DNA complex gel (2 g) and 1 ml serum-free medium were added in a glass bottle and incubated in a water bath at 37˚C. At different time points, ~100 µl release solution containing free P407 and the polymers/DNA complex were collected from the bottle (2.5 µg DNA was present in 100 µl release solution) and added to 400 µl fresh serum-free medium and into a 24-well plate. The cells were incubated at 37˚C with 5% CO 2 for 4 h. After 4 h incubation, culture medium was replaced with 500 µl culture medium containing 10% FBS and incubated at 37˚C with 5% CO 2 for 48 h. Eventually, culture medium was replaced with 100 µl CCLR and the plate was stirred for 30 min at room temperature. Data assessment was performed as previously described.
Statistical analysis. The data are presented as the means ± standard deviation. SPSS Statistics 17.0 (SPSS, Chicago, IL, USA) was used to calculate values. Data from two groups were compared using independent sample t-tests, whereas multiple groups were evaluated using one-way analysis of variance followed by Least Significant Difference post hoc tests. The experiment was repeated six times for statistical analysis. P<0.05 was considered to indicate a statistically significant difference.
Results and Discussion
Characterization of P407-PEI-K12. The PEI derivates of P407-PEI were synthesized by linking PEI (2 kDa) with P407, which was then conjugated with the bifunctional peptide K12 to prepare a novel non-viral gene delivery vector, P407-PEI-K12 (Fig. 1) . The synthesized peptide K12 was analyzed and identified by mass spectrometry and High Performance Liquid Chromatography ( Fig. 2A and B) . The molecular weight of K12 was 1,699.11 Da with 98.75% purity. As shown in Fig. 2C , the 1 H-NMR spectrum of P407-PEI was obtained. The -CH 2 CH 2 NH-and -CH 2 CH 2 O-proton peaks appeared at δ2.51-2.7 and δ3.25 ppm, respectively. The proton peaks of P407-PEI-K12 moved toward the lower magnet field compared to those of P407-PEI (Fig. 2D) . The-CH 2 CH 2 NH-proton peaks present in the δ2.51-2.70 ppm region were not found due to K12 attachment (Fig. 2D) . These alterations confirmed that the bifunctional peptide K12 had been successfully linked to P407-PEI.
Buffer capacity of P407-PEI-K12. The majority of cationic polymers have a high buffering capacity, which may disrupt endosomes during transfection, thereby facilitating escape of the polymer/DNA complex (21, 22) . As shown in Fig. 3 , the buffering capacity of P407-PEI-K12-l was slightly higher than P407-PEI-K12-h. Compared with pure water, P407-PEI-K12-l and P407-PEI-K12-h exhibited a markedly higher buffering capacity at all pH values, which indicated that the derived polymer could be a potential gene vector.
Particle size, zeta potential and morphologic observation.
As demonstrated in Fig. 4A , P407-PEI-K12 with numerous loose branches dispersed uniformly at room temperature, and the particle size ranged between 800 and 1,000 nm. After self-assembly with plasmid DNA, the morphology of P407-PEI-K12/DNA changed to a spherical shape with a particle size distribution of 200-500 nm (Fig. 4B) . As presented in Fig. 4C , the sizes of P407-PEI-K12-l/DNA and P407-PEI-K12-h/DNA particles decreased with the increasing w/w ratio, and stayed stable between 200 and 500 nm. Previous findings suggested that complexes ranging between 200 and 500 nm can effectively protect DNA (23) . In addition, the complex surface has to be positively charged in order to allow binding to the cell membrane, which is negatively charged. As shown in Fig. 4D , the zeta potential of P407-PEI-K12-l/DNA and P407-PEI-K12-h/DNA increased with increasing w/w ratio. P407-PEI-K12-l/DNA had a higher zeta potential compared to P407-PEI-K12-h/DNA, but their zeta potential was maintained within the range of 5-35 mV, which ensures good stability and transferability.
Analysis of the gel electrophoresis block and stability of the polymer/plasmid DNA complex. The DNA condensation capacity of P407-PEI-K12 was assessed by agarose gel electrophoresis. The plasmid DNA movement in the gel was retarded with increasing amount of polymers, since polymers bind to DNA and neutralize charges. When the ratio (w/w) of polymer to DNA exceeds the neutralization component, the complex exhibits a positive charge and stops moving toward the anode. In the present study, P407-PEI-K12-h, P407-PEI-K12-l and P407-PEI-10 were able to effectively condense the DNA at a ratio (w/w) of 1.2, 0.6 and 0.4, respectively (Fig. 5A-C) . With increasing ratio (w/w) of K12 to P407-PEI, the complex to DNA ratio (w/w) increased in order to efficiently condense DNA, possibly because the peptide shielded a partial positive charge on the surface of the complex. Because of the abundance of DNase I in tissue and blood, DNA degradation by DNase I is a barrier for in vivo gene delivery. Fig. 5D demonstrated that P407-PEI-K12 protected plasmid DNA from degradation by DNase I at various concentrations (0-72 I/µg presented in Fig. 5E , which indicated that P407-PEI-K12 can protect plasmid DNA from degradation, which is indicative of good stability of the polymer. The results suggested that DNA may not be dissociated by serum, suggesting that the complex would remain stable in blood circulation.
Cytotoxicity.
A correlation between cytotoxicity and polymer molecular weight was assessed. High molecular weight polymers (which contain more amino groups) compared to LMW polymers induced a higher cytotoxicity. The cytotoxicity of the degradable P407-PEI-K12 was evaluated by the MTT assay using Hela cells treated with PEI (25 kDa). P407-PEI-K12 and PEI 2 kDa exhibited markedly higher cell viability compared with PEI 25 kDa (Fig. 6 ). P407-PEI-K12 also demonstrated lower cytotoxicity at different concentrations, which indicated that the polymer may be suitable for gene delivery. The reduced cytotoxicity could therefore be attributed to the low amino group density and low toxicity of the building blocks (24) . It has previously been demonstrated that the ester bonds contained in P123-PEI-R13 can degrade into poloxamer oligomers and LMW PEI under physiological conditions (5). Similar to P123-PEI-R13, P407-PEI-K12 can be rapidly degraded and excluded from the cell, resulting in reduced cytotoxicity.
In vitro gene transfection of P407-PEI/DNA complex and P407-PEI-K12/DNA complex. All types of P407-PEI exhibited markedly higher transfection efficiency at w/w ratio of 20 and 30 compared with PEI 25 kDa, whereas P407-PEI-10 had the highest transfection efficiency compared to the others at a w/w ratio of 20 (Fig. 7) . Based on the optimal molar ratio of PEI to P407 of 10:1, peptide K12 was mixed with pretreated P407-PEI at a molar ratio of 2:1 and 10:1 to form P407-PEI-K12-l and P407-PEI-K12-h, respectively. As shown in Fig. 8A , the transfection efficiency of the P407-PEI-K12-h/DNA and P407-PEI-K12-l/DNA complexes was higher at a weight ratio of 20. Furthermore, P407-PEI-K12-h/DNA and P407-PEI-K12-l/DNA complexes exhibited maximal transfection efficiency when the weight ratio of polymer to DNA was 20 (Fig. 8B) . The gene transferability of all P407-PEI-K12/DNA complexes was higher compared to PEI 25 kDa, whereas the P407-PEI-K12-h/DNA complex exhibited the highest luciferase expression level. In addition, the P407-PEI-K12/DNA complex presented a higher gene transfection than P407-PEI-10/DNA complex at optimal conditions, suggesting that the functional peptide K12 may be necessary to modify P407-PEI for enhancing the transfection efficiency of the complex in vitro. Furthermore, the P407-PEI-K12-h/DNA complex had a higher gene transfection than P407-PEI-K12-l/DNA complex at optimal conditions, which implied that the transfection efficiency of the P407-PEI-K12/DNA complex was increased with the rising rates of K12. Furthermore, not only did the K12 peptide allowed cell targeting of P407-PEI-K12/DNA, but it also facilitated the cellular transport.
In vitro gene transfection of P407-PEI-K12/DNA complex with various concentrations of free P407. The P407-PEI-K12-h/DNA complex presented higher gene transfection than the P407-PEI-K12-l/DNA complex with free P407 ranging between 0 and 0.12% (Fig. 9) . The results further revealed that addition of free P407 into P407-PEI-K12/DNA complex solution may have a good effect on gene transfection, whereas P407-PEI-K12-h/DNA complex exhibited higher transfection efficiency compared with P407-PEI-K12-l/DNA complex with same concentrations of free P407. In addition, transfection efficiency was significantly enhanced by 0.09% free P407, showing that complex solution with the free P407 of 0.09% have the largest effect.
Release profile of P407 gel and P407/P407-PEI-K12-h/DNA complex gel. Free P407 can form a gel at concentrations ranging between 20 and 25% (25) . In the pre-experiment, it was revealed that gel formation was achieved at concentrations of 20-23%. As presented in Fig. 10A , the release rate gradually decreased with increasing concentrations of free P407. In addition, the half-life of the P407 gel was 213, 222, 236, and 259 min, at 20, 21, 22 and 23%, respectively, suggesting that all P407 gels may provide constant release. As presented in Fig. 10B , the half-life of the P407/P407-PEI-K12-h/DNA complex gel was 228 min, similar to that of 21 and 22% free P407. The release rate of the complex gel was 4.4 mg/min. Furthermore, the concentration of P407 in complex solution was 21% and the release rate of free P407 in polymer/DNA complex gel was 0.924 mg per minute, which accounted for 0.09%/ml of released medium and exhibited preferable transfection efficiency. The P407/P407-PEI-K12-h/DNA complex gel may meet the requirements of a follow-up study.
In vitro gene transfection of P407/P407-PEI-K12-h/DNA complex at different release times. The P407/P407-PEI-K12-h/DNA complex exhibited higher transfection efficiency compared with the P407-PEI-K12-h/DNA complex at various durations of sustained release (Fig. 11) . The transfection efficiency of P407/P407-PEI-K12-h/DNA complex was markedly higher compared to the P407-PEI-K12-h/DNA complex at 5-60 min under optimal conditions. The polymer in P407/P407-PEI-K12-h/DNA complex could be degraded within 60-300 min and the transfection efficiency of the P407/P407-PEI-K12-h/DNA complex was gradually decreased; however, it remained higher than the P407-PEI-K12-h/DNA complex. Therefore, when added into the P407-PEI-K12-h/DNA complex solution, free P470, a temperature-sensitive in situ gel, may not only have a good sustained release but also increase transfection efficiency, allowing stable gene expression.
In the present study, P407-PEI-K12 was synthesized by cross-linking LMW PEI with P407 and further coupling the bifunctional peptide K12. The K12 peptide has previously been demonstrated to retain its expected functionality and not be quenched by the PEI cation (26) . The synthesized P407-PEI-K12 demonstrated low cytotoxicity and high transfection efficiency. The novel polymer exhibited suitable buffer capacity, with good size ranges and zeta potential, and effectively prevented the degradation of plasmid DNA by DNase I, with a marked ability for serum tolerance. Prior to the present study, B16, U87 and Hela cells were chosen to perform comparative transfection experiments with luciferase plasmid, in order to evaluate the transfection efficiency of P407-PEI-K12 in several tumor cells; the results demonstrated that the transfection of P407-PEI-K12 in Hela cells was the best (data not shown). Furthermore, the transfection efficiency of P407-PEI-K12-h/DNA in Hela cells was higher at a polymer and plasmid DNA ratio of 20:1 (w/w). The addition of free P407 at 0.09% to the P407-PEI-K12-h/DNA solution exhibited excellent ability for transfection and sustainable gene expression. With a mass ratio of free P407 to polymer/DNA complex of 8.75:1, the concentration of free P407 was 21%, the half-life of the P407/P407-PEI-K12-h/DNA complex gel was 228 min and the dissolution amount of free P407 was accounted for 0.09% in the 1 ml aliquot of release liquid, which achieved good sustained release and exhibited higher transfection efficiency. The transfection efficiency of P407/P407-PEI-K12-h/DNA complex was markedly higher than the P407-PEI-K12-h/DNA complex at various release times. In conclusion, the addition of free P407 into P407-PEI-K12-h solution may be used as a potential sustained-release gene delivery system to enhance cell transfection and prolong gene expression, which can improve the efficacy of tumor therapy in a clinical setting.
